Agendia, a Dutch molecular cancer diagnostics firm, has opened a US clinical genomics laboratory in Huntington Beach, California. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments as administered by the US Centers for Medicare and Medicaid Services, the company stressed.
"Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the USA," said company chief executive Bernhard Sixt.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze